L.A. fires led to more than 400 additional deaths, study finds
In the study, published in the medical journal JAMA on Wednesday, researchers analyzed data on the number of deaths in Los Angeles County from Jan. 5 to Feb. 1, 2025 — the period when the Palisades and Eaton fires tore though the city — and estimated that 440 more deaths could be attributed to the fires, compared to the expected number based on data from previous years.
These additional deaths likely reflect a combination of factors, including increased exposure to poor air quality, which may exacerbate heart or lung conditions, the authors say. They also point to the impact of delays or interruptions in people's access to necessary health care during that period.
"The findings from this study underscore the need to complement direct fatalities estimates with alternative methods to quantify the additional mortality burden of wildfires and of climate-related emergencies more broadly," the authors wrote. "They also highlight the need for improved mortality surveillance during and after wildfire emergencies."
The study did have some limitations, including some provisional data, and it did not account for deaths that may have occurred after Feb. 1.
The authors suggest future research should look into the longer-term impacts of the wildfires as more data becomes available. They also urged more research into the causes contributing to excess deaths related to wildfires.
The JAMA Network also published two studies Wednesday examining the health impacts of the Maui wildfires, which devastated the island in August 2023.
In one study, researchers found substantial heart, lung and psychological health issues among a group of adults affected by the wildfires. Among the more than 1,000 study participants, nearly 63% had high blood pressure, nearly 50% reported depressive symptoms and about 22% exhibited FEV, or "forced expiratory volume," a measure of lung function.
Additionally, researchers found that members of the study group who resided within the fire perimeter had "significantly lower lung function" compared with those outside it.
A higher level of social support was associated with improved mental health outcomes, but researchers found it did not appear to improve physiological conditions like reduced lung function.
"As climate-driven disasters intensify, proactive strategies to monitor and mitigate their long-term health effects will be essential to protect vulnerable populations and enhance resilience," the authors wrote.
Another study focused on suicides and overdoses in the wake of the disaster. That research found that the fires did have an immediate effect on these types of deaths both in Maui and across Hawaii.
Using data from the U.S. National Center for Health Statistics from January 2014 through December 2023, researchers found the fires were associated with a 46% increase in the suicide and overdose death rate in all of Hawaii in August 2023, relative to other months, and a 97% increase that month in Maui alone.
During the 120-month study period, August 2023 accounted for both Maui's and other Hawaiian counties' highest monthly combined suicide and overdose death rate.
The authors note these findings highlight the importance of "rapidly deploying suicide and overdose prevention interventions during wildfire response and recovery phases," including interventions that reach beyond directly-impacted areas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
This Video Of Mariah Carey Finding Out That Katy Perry Went To Space Is The Funniest Thing I've Seen All Week, And You Need To Watch It
Back in April, Katy Perry and five others took a 10-minute trip to space thanks to Jeff Bezos's Blue Origin aerospace company, and it was basically all anyone talked about for about a week. Maybe even two. Blue Origin / Via Gilbert Flores / Getty Images Between the backlash and memes, the interviews and think-pieces, it's almost impossible to imagine that anyone with access to the internet could've missed the news. Which brings us to the one and only, Mariah Carey. Related: In a new interview with the BBC, radio host Scott Mills asked Mariah if she could ever see herself following in Katy's footsteps — only to very quickly realize she had no idea what he was talking about. Even with her big black shades on, the confusion on Mariah's face was evident. 'Did she go to space?' she said. Related: Mariah has a reputation for leaning into a bit every now and then if she's feeling shady; however, in this instance, she appeared genuinely baffled as she dug for answers: 'Where'd she go?!' she asked, looking around the room. Someone off camera chimed in to give Mariah the context that she needed — i.e., that Katy's space mission was rather brief — and the music icon was even more intrigued. 'Into orbit and back? She's like, floating in the…,' she said. 'And this is true?' BBC / Via Related: When Scott clarified that he was, in fact, not making it up, Mariah expressed her admiration, while also seeming totally unbothered by the whole thing, which is a skill in itself. 'Wow, alright Katy,' she said, totally deadpan. 'I'm not mad at her. That's pretty amazing.' And just when you thought the clip couldn't get any better, Scott returns to his initial question of, 'Would you do it?' to which she replied: 'I think I've done enough.' Indeed, you have, Mariah. It truly doesn't get more iconic than that. The video has only been up for a few hours, and already, people are obsessed — not only with the fact that Mariah had no idea about the space trip, but just how chill she is about the whole thing. 'I want to be THIS genuinely chill about actually everything,' one TikTok user wrote. ''I think I've done enough' says it all 🤣' added another. 'Mariah lives in her own World. everyone else is irrelevant 😅,' commented someone else, while another said: 'Only space she knows, is her own 🤣 - Queen Aura' Related: Well, if we needed any more confirmation that Mariah is simply not like the rest of us, then this was it. Do yourself a favor and watch the full clip here! More on this 14 Suuuuuper Awkward Moments From That Space LaunchMatt Stopera · April 14, 2025 'She Never Misses': People Are Obsessed With Mariah Carey's No BS Response To A Question About Jeff Bezos's WeddingEllen Durney · July 10, 2025 Katy Perry Sang "What A Wonderful World" While In Space, And No, This Isn't SatireNatasha Jokic · April 14, 2025 Also in Celebrity: Also in Celebrity: Also in Celebrity: Solve the daily Crossword
Yahoo
12 minutes ago
- Yahoo
RFK Jr. pulls funding for mRNA vaccines as scientists pursue breakthrough treatments for HIV, cancer, the flu and more
Health Secretary Robert F. Kennedy Jr. announced Tuesday that the federal government is canceling nearly $500 million in funding for the development of mRNA vaccines, a revolutionary new technology that was first put into widespread use during the COVID-19 pandemic. In a video explaining the decision posted to social media, Kennedy said that the Department of Health and Human Services has determined that 'mRNA technology poses more risk than benefits' for respiratory viruses like COVID-19. He also claimed that the pandemic showed 'mRNA vaccines don't perform well against viruses that affect the upper respiratory tract.' That statement runs counter to a wide body of research finding that COVID vaccines saved millions — if not tens of millions — of lives over the course of the pandemic. A total of 22 projects funded by a government agency called the Biomedical Advanced Research and Development Authority (BARDA) will be affected by the funding freeze, according to the department. A few projects that are in their final stages will be allowed to continue, but 'no new mRNA-based projects will be initiated.' 'This isn't just about vaccines. It's about whether we'll be ready when the next crisis hits. Cutting mRNA development now puts every American at greater risk,' Rick Bright, who directed BARDA in the early stages of the pandemic before being reassigned by the Trump administration, told NBC News. The decision doesn't mean that research into mRNA vaccines will stop entirely, but it does cut off a major source of funding that helped the vaccines become a reality in the first place. By the time the pandemic had started, the government had already given an estimated $337 million in grants for research into mRNA vaccines. That support over the course of decades put scientists in a position to make COVID vaccines available to the public at a record-shattering pace of less than a year. How do mRNA vaccines work? The 'm' in mRNA stands for messenger. In the most basic terms, it's a piece of genetic code that tells our cells what to do. Scientists have discovered how to harness this process to make vaccine development much faster and less expensive. Traditional vaccines typically use a dead or weakened version of a virus to stimulate an immune response that effectively teaches the body how to combat the real version if it ever encounters it. These types of vaccines can take a long time to develop because they rely on the slow, often complicated process of cultivating and modifying the actual virus into a safe and effective form. Using mRNA is much faster because the crucial ingredients can be created and customized in a lab. It took Moderna just two days to produce its mRNA vaccine for COVID in January 2020, before most people had ever even heard of the virus. The vaccines carry a snippet of mRNA that instructs the body to produce a small portion of a virus, usually a protein on its outer membrane, which is enough to trigger the same type of immune response that is prompted by traditional vaccines. The quicker process also means that existing mRNA vaccines can be modified more rapidly when viruses evolve. Despite Kennedy's claims, mRNA-based COVID vaccines have been found to be just as effective at preventing severe infections and death as vaccines made using other methods. After the vaccines became widely available, unvaccinated people were 11 times more likely to die of COVID than those who were fully vaccinated, according to data from the Centers for Disease Control and Prevention. Two researchers who helped achieve early breakthroughs in mRNA vaccines were awarded the Nobel Prize in 2023. Applications beyond COVID The introduction of COVID vaccines didn't just mark a turning point in the deadliest pandemic in modern history. It also provided evidence of mRNA's potential to protect people from a whole range of diseases. Just last week, researchers released promising results from early trials of new mRNA-based vaccines for HIV, a huge breakthrough in a pursuit that has confounded scientists for more than 40 years. There have been tremendous strides made in drugs that protect people from catching the virus or keep them healthy if they do contract it, but the limitations of those treatments still mean that more than 600,000 people are dying every year of AIDS — mostly in the developing world. Experts see a potential vaccine as a key to finally conquering the virus. There is also optimism that mRNA could be an effective tool in combating the seasonal flu. Current flu vaccines vary widely in effectiveness from year to year, and are only about 60% effective at their best, because it can be hard for experts to predict which strain of the virus will be more dominant in any given flu season. Several pharmaceutical companies are developing mRNA flu vaccines that could become a powerful tool for fighting influenza because of how quickly they can be adapted to match the nature of the virus at any given time. That speed could be especially important if a novel flu strain, like bird flu, causes a severe outbreak. There is even some promise that mRNA might one day be used to make a universal flu vaccine that covers all strains. The holy grail for mRNA is cancer. Though vaccines are typically used to prevent disease, there are several vaccines in development that show 'real hope' of being an effective treatment for people with cancer. Those include 'individualized' vaccines that are custom-made for each patient's specific needs. An mRNA vaccine for RSV is already available to certain high-risk adults. Other possible applications include the Zika virus and cytomegalovirus, an infection that is particularly dangerous for babies and people with compromised immune systems. Though experts say the rollback of U.S. government funding is a setback for these projects, some also expressed optimism that mRNA breakthroughs will continue to come even without America's support. 'Will this dent what's going on in the U.S.? Unquestionably,' Kate Bingham, who led the United Kingdom's COVID vaccine task force, told the Guardian. 'Does that mean it's negative for the world? Not necessarily.' Solve the daily Crossword
Fast Company
14 minutes ago
- Fast Company
Sources reveal the Trump administration's plans for cutting U.S. drug prices
The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according to a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt 'most favored nation' pricing under which U.S. drug costs match the lower rates offered to other wealthy countries, the White House official said. The U.S. is currently negotiating bilateral trade deals and setting tariff rates on the sector. The Trump administration has asked some companies for ideas on raising prices abroad, two of the sources said, describing multiple meetings over several months aimed at lowering U.S. prices without triggering cuts to research and development spending drugmakers insist would result. The White House official called the effort collaborative, saying both sides were seeking advice from each other. The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Donald Trump has repeatedly said he wants to narrow this gap to stop Americans from being 'ripped off.' The previously unreported discussions reflect the challenges Trump faces to achieve that goal, and are the backdrop to the letters he sent last week to CEOs of 17 major drugmakers, urging them to cut U.S. prices to match those paid overseas. Unlike in the U.S., where market forces determine drug prices, European governments typically negotiate directly with companies to set prices for their national healthcare systems. Anna Kaltenboeck, a health economist at Verdant Research, said European nations have leverage to drive pricing and are sometimes willing to walk away from purchasing medicines they deem too expensive. Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America — the industry's main lobby group — has always argued that cutting U.S. prices would stifle innovation by lowering R&D spending. PhRMA declined to comment on the private meetings. Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends. 'Prices can come down in the United States without being increased in other countries, and we can still get innovation,' she said. TOP PRIORITY Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry, according to a senior executive at a European drugmaker, who spoke on condition of anonymity about the confidential meetings. 'This is the key conversation right now with PhRMA and every company getting that message from Pennsylvania Avenue to a point that we are already executing on it,' the executive said, referring to the White House address. The company had already met with European governments on the issue, the executive added. An E.U. Commission spokesperson said it is in regular contact with the pharma industry and pointed to an agreement with the U.S. that should it impose tariffs on pharmaceuticals, they would be capped at 15%. When asked how the administration would support international drug price negotiations, the White House official referred Reuters to Trump's most favored nation executive order from May. That order directed trade officials to pursue trade and legal action against countries keeping drug prices below fair market value. In last week's letters, Trump complained that since the May executive order, most industry proposals had simply shifted blame for high prices or requested policy changes that would result in billions in industry handouts. A second source, a pharmaceutical executive who was not authorized to speak on the matter, said the Trump administration has been continually meeting with representatives of his company and had discussed strategies for raising drug prices internationally. 'There's a big push from the administration to drive up prices outside the U.S.,' the executive said. The executive said the Trump administration had been looking at using trade talks with the UK and EU as leverage, and considered pressuring countries to spend a higher percentage of GDP on new medicines or offering tariff breaks in exchange for higher drug spending. It was understood that the UK deal specifically aims to get the country to ramp up investment in branded medicines over time, the executive said. A spokesperson for the UK government said it would continue to work closely with the U.S. and its own pharmaceutical industry to understand the possible impact of any changes to drug pricing, without commenting on the trade talks. In April, over 30 industry CEOs including those from AstraZeneca, Bayer and Novo Nordisk signed a letter to European Union President Ursula von der Leyen saying Europe needed to rethink its pricing policies. 'It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction,' Kaltenboeck said, 'and it doesn't make much sense for them politically.'
